Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Germany's Merck Starts Swiss Project

by Michael McCoy
November 17, 2008 | A version of this story appeared in Volume 86, Issue 46

[+]Enlarge
Credit: Merck
Media and buffer preparation tanks at Merck's Corsier-sur-Vevey site.
Credit: Merck
Media and buffer preparation tanks at Merck's Corsier-sur-Vevey site.

Merck KGaA's Merck Serono division is spending some $375 million to expand its production site in Corsier-sur-Vevey, Switzerland. The project will allow the company to boost output of Erbitux, the cancer-fighting monoclonal antibody that it markets with ImClone Systems. By 2010, Merck will add two production suites with a combined 120,000 L of bioreactor capacity.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.